AXSM — Axsome Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $8.00bn
- $7.87bn
- $638.50m
Annual cashflow statement for Axsome Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -130 | -187 | -239 | -287 | -183 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 23 | 43.7 | 116 | 117 | 104 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.857 | 22.6 | -28.2 | 33.5 | -23.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -108 | -117 | -145 | -128 | -93.4 |
| Capital Expenditures | -0.308 | -0.702 | -0.582 | -0.27 | -0.48 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -53 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -0.308 | -53.7 | -0.582 | -0.27 | -0.48 |
| Financing Cash Flow Items | -0.485 | -3.46 | -25.2 | -12.6 | -21.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.1 | 285 | 331 | 57.8 | 101 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -97.4 | 114 | 185 | -70.8 | 7.58 |